Stockholm – Nov. 8, 2024 /PRNewswire/ — Third Quarter (July – September 2024) Order intake SEK 253.4 M (240.7) Net sales SEK 293.3 (252.9) Operating profit SEK 61.8 M (28,6) Profit after tax SEK 45.4 M (21,6) Earnings per share before/after dilution SEK 1.32 (0.63) Cash flow from operating activities SEK 60.5 M (124.4) Order backlog SEK 1,732.0 M (1,966.3) at the end of the period. Nine Months (January – September 2024) Order intake SEK 782.1 M (686.5) Net sales SEK 869.4 M (722.5) Operating profit SEK 186.9 M (70.5) Profit after tax SEK 143.5 M (50.0) Earnings per share before/after dilution SEK 4.19 (1.46) Cash flow from operating activities SEK 382.3 M (340.2).
Significant Events During the Second Quarter: Connect Proton Therapy Center in the USA has placed an order for RayStation. Iridium Network becomes the first center in the world to use RayCare with TrueBeam to treat a patient.
Significant Events After the End of the Reporting Period: GenesisCare in the UK has placed an order for RayStation. RaySearch now has more than 100 RayStation customers in China. Three centers in the French Unicancer network choose RayStation. Nina Grönberg has been appointed as the new CFO and will take office in January 2025. Institut Curie selects RayStation for proton planning. The Board has decided to raise the target for the operating margin to at least 25 (20) percent by 2026.
Webcast: CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch’s interim report for July-September 2024 in a webcast to be held in English on Friday, November 8, 2024, at 10:00 a.m. CET.
The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act.
RaySearch’s latest financial report showcases a positive growth trend, with increased order intake, net sales, operating profit, and other key metrics. The company’s expansion into new markets like the USA, UK, China, and France further strengthens its position as a global leader in the healthcare technology industry. With the appointment of a new CFO and ambitious targets for future operating margins, RaySearch is poised for continued success and growth in the coming years.
Effects on me:
As a consumer of healthcare services, the advancements made by RaySearch in proton therapy technology and treatment planning may result in more advanced and efficient treatment options becoming available to me in the future. This could potentially lead to improved outcomes and a higher quality of care for patients like myself.
Effects on the world:
RaySearch’s global expansion and partnerships with leading healthcare facilities around the world signify a growing demand for innovative and cutting-edge medical technologies. The adoption of RayStation by more institutions worldwide could potentially improve access to advanced cancer treatments and positively impact the global healthcare landscape.
Conclusion:
RaySearch’s impressive financial performance, strategic partnerships, and commitment to innovation position the company for continued success and growth in the healthcare technology sector. With a strong leadership team in place and ambitious targets for the future, RaySearch is well-positioned to make a significant impact on the industry and improve patient outcomes on a global scale.
